Business & Development - Licensing out
Strong position of our company on the market, is among other result of efficient work of highly professional staff of the Business Development Division.
The main objective of the Development Division is launching of new products corresponding to market demands.
This task is realized either by licensing in or internal development in our modern research laboratory department.
Sanitas Group, leader in dermatology in Poland and significant player in CEE region looks for strategic partners to market its dermatology products in West European countries. List of products with availability of dossiers appended.
All dossiers we offer were/will be developed in house, are in CTD format and contain clinical trials. For certain products we are/we will be able to offer also DCP slots.
Sanitas’ dossiers available for licensing out in 2010
| API | Pharmaceutical form | Dossier availability with CT |
| terbinafine | cream | available |
| mometasone | solution** | available |
| mometasone | cream | 10.2010 |
| betamethasone + salicylic acid | ointment | 11.2010 |
| betamethasone + salicylic acid | solution** | 11.2010 |
| adapalene | cream* | 01.2011 |
| adapalene | gel* | 01.2011 |
*without clinical trials – CT possible
**bio-waiver
We can also offer Marketing Authorizations/Pending regulatory procedures.
At present we offer:
| ACTIVE SUBSTANCE | STRENGTH | FORM | TERRITORY | REGISTRATION STATUS |
| Mycophenolate | 500mg | TABS | Poland, Czech Republic, Slovakia, Romania, Hungary, Latvia, Lithuania | MA available |
| Tacrolimus | 0,5 mg, 1mg, 5 mg | CAPS | Czech Republic* | Regulatory procedure pending |
* MRP possible out of Czech Republic for Poland, Bulgaria, Slovakia, Romania, Hungary, Latvia, Lithuania.
Contact:
Barbara Olszewska
e-mail: barbara.olszewska@jelfa.com.pl
tel. +48 75 64 33 692



